A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1‐Inclined Immune Response against Visceral …
Immunotherapy, a treatment based on host immune system activation, has been shown to
provide a substitute for marginally effective conventional chemotherapy in controlling …
provide a substitute for marginally effective conventional chemotherapy in controlling …
Three decades of clinical trials on immunotherapy for human leishmaniases: a systematic review and meta-analysis
CA Mota, J Oyama, M Souza Terron Monich… - …, 2021 - Taylor & Francis
Aim: Current treatments for leishmaniases are not satisfactory, thus alternatives are needed.
We searched for clinical trials with immunotherapeutic approaches for patients with …
We searched for clinical trials with immunotherapeutic approaches for patients with …
Leishmaniosis
First Described: The cause of visceral leishmaniasis was first described in India in 1903
(separately by William Leishman and Charles Donovan).• Causes: Canine and feline …
(separately by William Leishman and Charles Donovan).• Causes: Canine and feline …
Vitamin D and canine leishmaniasis
C Martori Muntsant - 2021 - ddd.uab.cat
Les leishmaniosis són un grup de malalties causades per protozous del gènere Leishmania
que es transmeten per vectors. La leishmaniosi visceral (LV) humana pot ser mortal si no es …
que es transmeten per vectors. La leishmaniosi visceral (LV) humana pot ser mortal si no es …